William K Heiden
CIK 1214939 · President & CEO · last filed 2026-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AMAG price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1100 WINTER STREET
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ATRA | Director | 34,188 | $8.35 | $285.5K | $25.3K | 14 | 2026-06-11 |
| MGNX | Director | 114,750 | $2.19 | $251.3K | $150.5K | 7 | 2026-05-20 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | President & CEO | 424,612 | — | — | -$7.16M | 30 | 2020-03-04 |
| GTC BIOTHERAPEUTICS INC (GTCB) Delisted | Director | — | — | — | $0 | 1 | 2009-10-05 |
Recent Filings · Page 3 of 6
53 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-02-27 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Grant (A) | +163,000 | $0 | EDGAR |
| 2019-02-26 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Tax (F) | −2,957 | -$45.9K | EDGAR |
| 2018-08-08 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Sell (S) | −5,000 | -$125.0K | EDGAR |
| 2018-06-18 | ATRA | Grant (A) | +1,500 | $0 | EDGAR |
| 2018-06-05 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Sell (S) | −20,000 | -$500.0K | EDGAR |
| 2018-03-06 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Mixed | +80,454 | -$221.5K | EDGAR |
| 2017-06-12 | ATRA | Grant (A) | +5,000 | $0 | EDGAR |
| 2017-05-10 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Tax (F) | −19,085 | -$354.0K | EDGAR |
| 2017-02-27 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Grant (A) | +85,000 | $0 | EDGAR |
| 2017-01-05 | ATRA | Grant (A) | +2,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.